Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to standard therapy and with relapsed or progressive disease
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Dinutuximab beta (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms ChIm-NB-PL
- 19 Nov 2021 Planned End Date changed to 13 Oct 2026.
- 19 Nov 2021 Status changed from not stated to recruiting.
- 22 Oct 2021 New trial record